Lupin gets FDA blessing for generic Vigabatrin
Vigabatrin for Oral Solution had a market value of roughly $275 million, according to December 2021 IQVIA data.
The Food and Drug Administration has given Lupin the green light for its anti-epilepsy drug, Vigabatrin for Oral Solution, in a dosage strength of 500 mg.
The product is the generic of Lundbeck's Sabril for Oral Solution.
[Read more: Lupin obtains FDA OK for generic Renagel]
The medication will be manufactured at Lupin's manufacturing facility in Goa.
Vigabatrin for Oral Solution had a market value of roughly $275 million, according to December 2021 IQVIA data.
[Read more: Lupin receives FDA OK for generic Truvada]